178 related articles for article (PubMed ID: 36544044)
1. TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
Fan L; Gong Y; He Y; Gao WQ; Dong X; Dong B; Zhu HH; Xue W
Oncogene; 2023 Feb; 42(8):559-571. PubMed ID: 36544044
[TBL] [Abstract][Full Text] [Related]
2. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
3. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
4. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
[TBL] [Abstract][Full Text] [Related]
5. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract][Full Text] [Related]
7. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Kim DH; Sun D; Storck WK; Welker Leng K; Jenkins C; Coleman DJ; Sampson D; Guan X; Kumaraswamy A; Rodansky ES; Urrutia JA; Schwartzman JA; Zhang C; Beltran H; Labrecque MP; Morrissey C; Lucas JM; Coleman IM; Nelson PS; Corey E; Handelman SK; Sexton JZ; Aggarwal R; Abida W; Feng FY; Small EJ; Spratt DE; Bankhead A; Rao A; Gesner EM; Attwell S; Lakhotia S; Campeau E; Yates JA; Xia Z; Alumkal JJ
Clin Cancer Res; 2021 Sep; 27(17):4923-4936. PubMed ID: 34145028
[TBL] [Abstract][Full Text] [Related]
8. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
[TBL] [Abstract][Full Text] [Related]
9. A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression.
Naderinezhad S; Zhang G; Wang Z; Zheng D; Hulsurkar M; Bakhoum M; Su N; Yang H; Shen T; Li W
Cancer Lett; 2023 Sep; 571():216333. PubMed ID: 37543278
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
11. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
[TBL] [Abstract][Full Text] [Related]
12. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of MAML1 inhibits proliferation and induces apoptosis of T-cell acute lymphoblastic leukemia cells through SP1-dependent inactivation of TRIM59.
Cheng H; Chen L; Hu X; Qiu H; Xu X; Gao L; Tang G; Zhang W; Wang J; Yang J; Huang C
J Cell Physiol; 2019 Apr; 234(4):5186-5195. PubMed ID: 30370525
[TBL] [Abstract][Full Text] [Related]
14. FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer.
Zhou Y; Ou L; Xu J; Yuan H; Luo J; Shi B; Li X; Yang S; Wang Y
Cell Death Dis; 2021 Jul; 12(7):668. PubMed ID: 34215720
[TBL] [Abstract][Full Text] [Related]
15. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
[TBL] [Abstract][Full Text] [Related]
16. The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer.
Lim SC; Geleta B; Maleki S; Richardson DR; Kovačević Ž
J Biol Chem; 2021 Dec; 297(6):101414. PubMed ID: 34785213
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
[TBL] [Abstract][Full Text] [Related]
18. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer.
Cheng WC; Wang HJ
Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
20. CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.
Wen YC; Tram VTN; Chen WH; Li CH; Yeh HL; Thuy Dung PV; Jiang KC; Li HR; Huang J; Hsiao M; Chen WY; Liu YN
Cell Death Dis; 2023 May; 14(5):304. PubMed ID: 37142586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]